[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563969":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":51,"collaborators":53,"id":57,"slug":10,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"CerbaXpert","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Infected patients",null,"Patients infected with hepatitis B virus",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Sabrina KALI, Dr.","CONTACT","33762376831","kali.rinasab@gmail.com",[19,36],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Cerba Xpert","NOT_YET_RECRUITING","Frépillon","Ile de Franace","95000","France",{"type":27,"coordinates":28},"Point",[29,30],2.20528,49.05216,{"lat":30,"lon":29},[33],{"name":14,"role":15,"phone":34,"phoneExt":10,"email":35},"00337632376831","skali@cerbaresearch.com",{"facility":37,"status":38,"city":25,"state":39,"zip":40,"country":25,"cosmosGeoPoint":41,"geoPoint":45,"contacts":46},"Cerballiance Chemin vert","RECRUITING","Paris","75000",{"type":27,"coordinates":42},[43,44],-0.84802,45.60366,{"lat":44,"lon":43},[47],{"name":48,"role":15,"phone":49,"phoneExt":10,"email":50},"Sabrina Kali Dr. Sabrina Kali, Doctor","+33 621441566","sabrina.kali@cerbaxpert.com",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[54],{"name":55,"class":56},"Bioneer Corporation","UNKNOWN","100563969",false,"NCT06623071","Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96\u002F384","Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation™FA 96\u002F384","BIOPERF-HBV","Inclusion Criteria:\n\nThe patient to be included in this study must be able to understand the purpose research, in order to give free and informed consent.\n\n* Subject aged over 18\n* Subject presenting himself at the investigation center and responding to one of these two criteria:\n\n  * Subject presenting with a prescription for determination HBV viral load\n  * Subject with previously confirmed HBV infection by CE marked tests.\n* Subject capable of understanding the aim of the research having given express free and informed consent\n* Subject affiliated to or beneficiary of a social security system\n\nExclusion Criteria:\n\nProtected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial decision or administrative\n\n• Subject participating in another clinical study","ALL","18 Years",{"count":67,"type":68},45,"ESTIMATED","1 Day","OBSERVATIONAL","As part of the CE marking of a hepatitis B diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017\u002F746).\n\nCerba Xpert CRO of the Cerba Healthcare group promoted this performance study by setting up a prospective collection of blood samples from patients with hepatitis B virus and whose viral load is positive. This prospective collection will be carried out in 3 laboratories of the Cerba Healthcare group.",[73],"Hepatitis B",[75],"HBV","2025-03-24",{"date":78,"type":79},"2025-03-26","ACTUAL",{"date":81,"type":79},"2024-10-01",{"date":83,"type":68},"2025-05-31",{"name":5,"class":6},2]